2025.12. 02 以上海交大医学院附属新华医院为例，上周儿科急诊量上升了约20%，两个院区平均每日接诊量达到 1000人左右。 仁济医院儿科医生提醒，今年需特别警惕甲型H3N2毒株，与去年的H1N1相比，变异速度更快，传 染性更强。更易引发儿童持续高热和下呼吸道受累，增加支气管炎、肺炎风险。 另据北京儿童医院数据，近期流感阳性检出率明显增加。为充分接收患儿，医院开设不限号门诊、增 加医生出诊单元、启动门诊动态支援等。内科/发热咳嗽门诊开设白班、小夜班、大夜班，24小时接 诊。 儿童是流感防控的重点人群。相关研究数据显示，我国＜5岁低龄儿童流感疾病负担沉重：0至14岁 儿童每千人流感发病率最高，是15至59岁人群的超过3倍；＜5岁的低龄儿童是流感重症高危群体， 易并发肺炎、急性呼吸窘迫综合征（ARDS）、急性坏死性脑病等，威胁生命安全。 不过，目前针对＜5岁低龄儿童的流感抗病毒治疗选择较为有限，国内仅有神经氨酸酶抑制剂（如奥 司他韦）获批用于<5岁儿童流感抗病毒治疗。尽管该类药物安全性尚可，但在临床应用中依然存在 恶心、呕吐等不良反应，并且需要每天2次连用5天。 本文字数：1156，阅读时长大约2分钟 作 ...

儿童是流感防控的重点人群。相关研究数据显示，我国＜5岁低龄儿童流感疾病负担沉重：0至14岁儿童 每千人流感发病率最高，是15至59岁人群的超过3倍；＜5岁的低龄儿童是流感重症高危群体，易并发肺 炎、急性呼吸窘迫综合征（ARDS）、急性坏死性脑病等，威胁生命安全。 不过，目前针对＜5岁低龄儿童的流感抗病毒治疗选择较为有限，国内仅有神经氨酸酶抑制剂（如奥司 他韦）获批用于<5岁儿童流感抗病毒治疗。尽管该类药物安全性尚可，但在临床应用中依然存在恶 心、呕吐等不良反应，并且需要每天2次连用5天。 此外，近年来国家流感中心耐药监测数据提示耐药率也呈上升趋势，因此在低龄儿童流感抗病毒治疗领 域仍有很大的未满足需求。 在这一背景下，业内呼吁加大对儿童用流感抗病毒药物的研发。近期，首都医科大学附属北京儿童医院 赵成松教授团队牵头完成了玛巴洛沙韦干混悬剂在中国1至＜5岁儿童流感患者中的安全性、临床及病毒 学结果的临床研究，有望为扩大该药物的适应症提供临床证据，这也是首个聚焦中国1至＜5岁流感儿 童，评估玛巴洛沙韦干混悬剂有效性与安全性，将为中国低龄儿童流感抗病毒治疗提供新的选择。 目前针对＜5岁低龄儿童的流感抗病毒治疗选择较为 ...

另据北京儿童医院数据，近期流感阳性检出率明显增加。为充分接收患儿，医院开设不限号门诊、增加 医生出诊单元、启动门诊动态支援等。内科/发热咳嗽门诊开设白班、小夜班、大夜班，24小时接诊。 儿童是流感防控的重点人群。相关研究数据显示，我国<5岁低龄儿童流感疾病负担沉重：0至14岁儿童 每千人流感发病率最高，是15至59岁人群的超过3倍；<5岁的低龄儿童是流感重症高危群体，易并发肺 炎、急性呼吸窘迫综合征（ards）、急性坏死性脑病等，威胁生命安全。<> 不过，目前针对<5岁低龄儿童的流感抗病毒治疗选择较为有限，国内仅有神经氨酸酶抑制剂（如奥司 他韦）获批用于<5岁儿童流感抗病毒治疗。尽管该类药物安全性尚可，但在临床应用中依然存在恶 心、呕吐等不良反应，并且需要每天2次连用5天。<> 第一财经记者今日从上海市儿童医院以及上海交大医学院附属仁济医院、上海交大医学院附属新华医院 等多家医院儿科了解到，近期门急诊接诊量均有较为明显的上升，基本上以流感患儿为主。 以上海交大医学院附属新华医院为例，上周儿科急诊量上升了约20%，两个院区平均每日接诊量达到 1000人左右。 仁济医院儿科医生提醒，今年需特别警惕甲型H3N2毒株 ...

Market Performance - The Hang Seng Healthcare Index increased by 2.69% as of September 5, 2025, with notable gains from stocks such as Eucan Vision Bio-B (+13.93%), 3SBio (+11.67%), and CanSino-B (+10.58%) [3] - The Hang Seng Healthcare ETF (513060) rose by 2.36%, closing at 0.74 CNY, and has seen a 5.57% increase over the past week [3] - The Hang Seng Innovation Drug Selection Index surged by 3.33%, with 3SBio and CanSino-B also showing significant increases [5] - The Innovation Drug Selection ETF (520690) increased by 2.61%, reaching 1.06 CNY, and has recorded a 6.60% rise over the past week [5] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover rate of 25.37% with a trading volume of 1.917 billion CNY, indicating active market participation [3] - The average daily trading volume for the Hang Seng Healthcare ETF over the past week was 3.088 billion CNY, ranking it first among comparable funds [3] - The Innovation Drug Selection ETF had a turnover rate of 34.1% with a trading volume of 124 million CNY, also reflecting active trading [5] - The average daily trading volume for the Innovation Drug Selection ETF over the past week was 237 million CNY [5] New Drug Developments - A new pediatric influenza treatment, the Mavirovir granules, developed by Xiansheng Pharmaceutical and Antikang Bio, has had its market application accepted, targeting children aged 2-11 [6] - The HRS-4729 injection by Heng Rui Pharmaceutical has received clinical trial approval, aiming to be a first-in-class triple receptor agonist for weight loss and liver fat reduction [6][7] Institutional Insights - The introduction of the first domestic pediatric influenza drug is expected to address the seasonal demand for pediatric medications, potentially boosting sentiment in the anti-infection and pediatric channels [7] - The clinical approval of Heng Rui's triple receptor agonist is anticipated to enhance the long-term outlook for local companies in the GLP-1 expansion mechanism, increasing interest in related CRO/CDMO and metabolic pipeline companies [7][8] ETF Overview - The Hang Seng Healthcare ETF has a current size of 7.463 billion CNY, ranking it among the top third of comparable funds [10] - The ETF closely tracks the Hang Seng Healthcare Index, which reflects the performance of healthcare-related securities listed in Hong Kong [10] - The top ten weighted stocks in the Hang Seng Healthcare Index account for 62.87% of the index, including companies like BeiGene and Innovent Biologics [10] - The Innovation Drug Selection Index also has a significant concentration, with its top ten stocks representing 78.87% of the index [10]

Group 1 - The first domestically developed pediatric influenza antiviral drug, Maduonosawei granules, has had its market application accepted, targeting the treatment of influenza A and B in children aged 2 to 11 without complications. This marks a significant milestone for the Chinese pharmaceutical industry [1] - The approval of this pediatric drug is expected to provide a new growth point for Xiansheng Pharmaceutical and enhance its competitiveness in the influenza drug market, while also showcasing the innovative drug development capabilities of Antikang Bio [1] Group 2 - Huasheng Technology announced plans to re-list the transfer of a 51% stake in its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., with a listing price of 42.5 million yuan. The company has not yet found a suitable buyer after two rounds of bidding, indicating potential market valuation discrepancies [2] - The failure to attract qualified buyers may reflect concerns regarding the future development, competitive landscape, and financial status of Kangyu Pharmaceutical, making the outcome of the re-listing uncertain [2] Group 3 - Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received domestic approval for its Amlodipine Besylate tablets, a commonly used medication for regulating vascular pressure, with annual sales expected to reach 1.216 billion yuan in 2024 [3] - This approval enhances the product line of the company and its subsidiaries, improving market competitiveness, although the market is already crowded with numerous participants [3] Group 4 - Medisi's wholly-owned subsidiary, Medisi Puya Pharmaceutical Technology (Shanghai) Co., Ltd., has been sued for 159 million yuan due to a technical service contract dispute, with the case already filed but not yet heard [4] - The uncertainty surrounding this lawsuit may increase operational risks for the company and could lead to investor concerns regarding its future development [4] Group 5 - Shanghai Laishi announced that several executives, including the vice chairman and general manager, plan to increase their shareholdings in the company, with a total investment of no less than 6 million yuan sourced from personal funds [5] - Executive share purchases are generally viewed as a positive signal in the capital market, potentially attracting more investor interest and driving up stock prices, although the effectiveness of this plan will depend on market conditions and the company's actual performance [5]